Oligonucleotides may be universal primers and probes. Method may use these oligonucleotides for detecting or detecting and quantifying a nucleic acid acting as a universal internal control. A primer pair includes a first primer having SEQ ID NO: 1 or a complement thereof and a second primer having SEQ ID NO: 2 or a complement thereof. A probe includes SEQ ID NO: 3 or a complement thereof, preferably wherein each of the nucleotides in position 4, 5, 6, 8, 9, 10, 11 and 12 of SEQ ID NO: 3 is replaced with a corresponding locked nucleic acid (LNA) unit (SEQ ID NO: 4).

Embodiments of a method and/or system can include generating a set of target-associated molecules (e.g., spike-in molecules) associated with one or more biological targets; generating one or more spike-in mixtures based on processing the set of target-associated molecules with one or more samples including the one or more biological targets; performing one or more Sanger sequencing operations on the one or more spike-in mixtures; determining one or more abundance metrics based on chromatogram-related outputs from the one or more Sanger sequencing operations; and/or facilitating characterization of one or more medical conditions based on the one or more abundance metrics.

Embodiments of a method and/or system can include generating a set of target-associated molecules (e.g., spike-in molecules) associated with one or more biological targets; generating one or more spike-in mixtures based on processing the set of target-associated molecules with one or more samples including the one or more biological targets; performing one or more Sanger sequencing operations on the one or more spike-in mixtures; determining one or more abundance metrics based on chromatogram-related outputs from the one or more Sanger sequencing operations; and/or facilitating characterization of one or more medical conditions based on the one or more abundance metrics.

The present invention belongs to the field of nucleic acid detection, particularly in-vitro diagnostics. The invention concerns amongst others the amplification of at least one or more target nucleic acid that may be present in at least one sample using an inventive control, which comprises a particle comprising a polycationic compound and a nucleic acid. The present invention relates also to uses of the inventive controls, methods for the preparation, diagnostic tools and kits.

The present invention belongs to the field of nucleic acid detection, particularly in-vitro diagnostics. The invention concerns amongst others the amplification of at least one or more target nucleic acid that may be present in at least one sample using an inventive control, which comprises a particle comprising a polycationic compound and a nucleic acid. The present invention relates also to uses of the inventive controls, methods for the preparation, diagnostic tools and kits.

Methods, compositions, and kits are provided for quantification of genome editing.

Methods, compositions, and kits are provided for quantification of genome editing.

An expression vector, comprising a first reporter nucleic acid sequence operably linked to a first expression control sequence comprising a promoter; and a second reporter nucleic acid sequence operably linked to a second expression control sequence that comprises a response element that is activated or inactivated as one or more of the cells differentiate or dedifferentiate. Methods and kits for imaging and monitoring stem cells comprising the expression vector are also provided.

An expression vector, comprising a first reporter nucleic acid sequence operably linked to a first expression control sequence comprising a promoter; and a second reporter nucleic acid sequence operably linked to a second expression control sequence that comprises a response element that is activated or inactivated as one or more of the cells differentiate or dedifferentiate. Methods and kits for imaging and monitoring stem cells comprising the expression vector are also provided.

Methods and materials for detection of aneuploidy and other chromosomal abnormalities using fetal tissue are disclosed. Results can be obtained rapidly, without cell culture. The method uses digital PCR for amplification and detection of single target sequences, allowing an accurate count of a specific chromosome or chromosomal region. Specific polynucleic acid primers and probes are disclosed for chromosomes 1, 13, 18, 21, X and Y. These polynucleic acid sequences are chosen to be essentially invariant between individuals, so the test is not dependent on sequence differences between fetus and mother.